Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Chen-Te Huang, Tai-Chung Tseng

Clin Mol Hepatol. 2024;30(2):154-156. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0120

View: 652 Download: 27

Hung-Yao Lin, Tai-Chung Tseng

Clin Mol Hepatol. 2022;28(2):181-182. Published online February 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0028

View: 3828 Download: 116 Web of Science: 3 Crossref: 3

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0012

View: 13004 Download: 344 Web of Science: 20 Crossref: 23

Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(2):281-282. Published online March 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0072

View: 3510 Download: 99 Web of Science: 5 Crossref: 5

1 |

Viewed By 5176	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5034	MAFLD: How is it different from NAFLD?
Viewed By 4978	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3673	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3628	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 51	MAFLD: How is it different from NAFLD?

Search